Loading
TELA Bio, Inc. Stock: price and insider trades · United States
2 insiders bought €161k of shares over the last 90 days, the latest by Capper Joseph H, filed 18 Sept 2026.
TELA Bio, Inc.: what insiders have been doing
This page follows insider dealings at TELA Bio, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. From 22 October 2025 to 22 October 2026, the disclosure feed for TELA Bio, Inc. logged 33 filings by 10 insiders.
Not one open-market sale was filed. On the buying side, 3 insiders reported 7 purchases totalling €3.6M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. One trade stands out by size: a purchase of €3.4M from EW Healthcare Partners Fund 2, L.P., disclosed on 17 November 2025. Among those who bought: 1 senior executive and 1 chief executive.
Compared with its exchange (3,169 companies, median 24 filings), a count of 33 filings is above the norm. Looking back to 2019, when coverage begins, insiders filed 246 purchases and 7 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 80.3 m USD and net income of -38.8 m USD.
The data flag 3 purchases as part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The latest purchase dates back some time: it was published 35 days ago, on 18 September 2026. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. US insiders must file a Form 4 within two business days of a trade.
Elsewhere in the same sector, our signals recently picked up insider purchases at UCB. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
420
Thresholds
n/a
Buy Volume
€45M
246 ops. · all time
Sell Volume
€4M
7 ops. · all time
Who traded when
BuySaleJoseph H. Capper4 buys
Heather C. Getz2 buys
EW Healthcare Partners Fund 2, L.P.1 buy
Since the insiders bought
- -25.0%Entry US$1.30 · Close 16 Oct 2026 US$0.98
- +52.6%Entry US$0.64 · Close 16 Oct 2026 US$0.98
- -35.1%Entry US$1.18 · Close at T+90 US$0.77
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate TELA Bio, Inc. Strong Buy (bullish), based on 5 analysts. Average price target: US$1.90.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 23,135 of 26,248 companies
23.7
score / 100
Value3
Quality45
FCF yld-59%
Earn yld-80%
EV/EBITDA·
ROE·
Gross mgn68%
Net mgn-48%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.08
Analyst consensus
5 analystsStrong buy
US$1.00Target US$1.90(+76%)US$2.50
Income statement
RevenueUS$80.3M
Gross profitUS$54.3M68% margin
EBITDA-US$32.3M-40% margin
Net income-US$38.8M-51.5% margin
Valuation
PER (forward)-2.4x
P/Book6.4x
Beta1.36
Balance sheet & cash
Market capUS$48.8M
Total debtUS$56.2M
Free Cash Flow-US$28.7M
Profitability & ownership
ROE-616.6%
ROA-33.4%
% insiders7.1%
% institutions63.3%
Last declaration on 19 October 2026
Declarations420 total
19,801 shares@ US$1.010.046% mcap10.7% of flowCommon StockSEC:0001456817-26-000017:0
16,089 shares@ US$1.010.037% mcap50.2% of flowCommon StockSEC:0001685640-26-000006:0
50,000 shares@ US$1.16530.13% mcap30.2% of flowCommon StockSEC:0001456817-26-000015:0
Canonical exit: 15 Dec 2026 (T+90)
25,000 shares@ US$1.22120.068% mcap15.9% of flowCommon StockSEC:0001456817-26-000015:1
Canonical exit: 16 Dec 2026 (T+90)
25,000 shares@ US$1.02010.056% mcap13.2% of flowCommon StockSEC:0001456817-26-000013:0
Canonical exit: 13 Dec 2026 (T+90)
50,000 shares@ US$1.05880.12% mcap27.4% of flowCommon StockSEC:0001456817-26-000013:1
Canonical exit: 14 Dec 2026 (T+90)
12,500 shares@ US$0.66490.014% mcap44.2% of flowCommon StockSEC:0001481485-26-000008:0
Canonical exit: 15 Nov 2026 (T+90)
15,000 shares@ US$0.69780.018% mcap55.8% of flowCommon StockSEC:0001481485-26-000006:0
Canonical exit: 12 Nov 2026 (T+90)
500,000 shares0Common StockSEC:0001481485-26-000004:0
6,227 shares@ US$0.7850.0083% mcap100.0% of flowCommon StockSEC:0001456817-26-000011:0
20,930 shares@ US$0.7850.028% mcap100.0% of flowCommon StockSEC:0001685640-26-000003:0
11,925 sharesCommon StockSEC:0001456817-26-000009:0
11,675 sharesCommon StockSEC:0001456817-26-000009:1
4,189 shares@ US$0.71745.3% of flowCommon StockSEC:0001984584-26-000002:1
1,352 shares@ US$0.7661.8% of flowCommon StockSEC:0001984584-26-000002:2
4,780 shares@ US$0.71740.9% of flowCommon StockSEC:0001591474-26-000002:1
5,234 shares@ US$0.7661.0% of flowCommon StockSEC:0001591474-26-000002:2
12,494 shares@ US$0.71741.6% of flowCommon StockSEC:0001195881-26-000002:1
11,631 shares@ US$0.7661.6% of flowCommon StockSEC:0001195881-26-000002:2
3,900 shares@ US$0.78520.6% of flowCommon StockSEC:0001195881-26-000002:3
795 shares@ US$0.7951.4% of flowCommon StockSEC:0001899973-26-000002:1
1,590 shares@ US$0.71742.6% of flowCommon StockSEC:0001899973-26-000002:2
423 shares@ US$0.7660.7% of flowCommon StockSEC:0001899973-26-000002:3
3,385 shares@ US$0.71741.7% of flowCommon StockSEC:0001899089-26-000002:1
4,061 shares@ US$0.7662.1% of flowCommon StockSEC:0001899089-26-000002:2
25 of 420 declarations
About TELA Bio, Inc.
TELA Bio, Inc. is a U.S.-based medical technology company listed on the NASDAQ market in the United States (United States). Founded in 2012 and headquartered in Malvern, Pennsylvania, the company focuses on soft-tissue reconstruction and hernia repair solutions designed to preserve and restore the patient’s anatomy while reducing long-term exposure to permanent synthetic materials. Its headquarters and R&D activities are centered in Malvern, in the greater Philadelphia area, which supports a commercial-stage operating model with a strong clinical and product-development orientation.
TELA Bio’s core franchise is its OviTex portfolio, a family of reinforced tissue matrices used primarily in hernia repair and abdominal wall reconstruction. The portfolio includes products for open, laparoscopic, and robotic-assisted procedures, as well as versions tailored to plastic and reconstructive surgery. This product set is the company’s key differentiator: it targets surgeons who want an alternative to conventional permanent synthetic mesh and to some biologic matrices, while still seeking reinforcement strength and favorable handling characteristics in the operating room. The company’s strategy is built around the idea that surgeons increasingly value solutions that align with natural healing and tissue remodeling.
Read moreShow less
From a competitive standpoint, TELA Bio operates in a large and clinically important market. Hernia repair is one of the most common surgical categories in the U.S., and the company’s SEC filings emphasize a meaningful addressable opportunity for OviTex across ventral, inguinal, and complex abdominal wall indications. The company’s commercial footprint remains primarily U.S.-driven, with a direct sales focus, but it has also been building an international presence, particularly in Europe. That international expansion is still early relative to the U.S. business, yet it has become a more visible part of the growth story.
Recent corporate developments suggest an execution-focused phase for the business. In May 2026, TELA Bio reported first-quarter 2026 revenue of $19.1 million, up 3% year over year, and highlighted 41% year-over-year growth in European revenue. The company also announced the U.S. commercial launch of OviTex LTR, described as a fully resorbable, tissue-based hernia repair solution. In addition, management disclosed a strategic board refreshment aimed at accelerating growth and driving the company toward profitability. For investors, TELA Bio remains a niche but differentiated medtech name: a small-cap commercial-stage platform with a focused product line, a clear surgical use case, and growing evidence of geographic diversification beyond its core U.S. market.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
